BCL2L1 and neoplasm: However, whilst the goal of achieving a potent dual Bcl-2/Bcl-xL inhibitor with activity across a broad range of tumour types with manageable thrombocytopenia risk was achieved dose limiting cardiovascular toxicity was observed during preclinical development thus AZD4320 could not be progressed to the clinic.